Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03834519 |
|---|---|
| Brief Title: | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010) |
| First Submitted : | February 6, 2019 |
| First Submitted that Met QC Criteria : | February 6, 2019 |
| First Posted : | February 8, 2019 |
| Results First Submitted : | March 2, 2023 |
| Results First Posted with QC Comments : | March 28, 2023 |
| Results First Submitted that Met QC Criteria : | April 18, 2023 |
| Results First Posted : | April 20, 2023 |
| Last Update Submitted that Met QC Criteria : | January 31, 2024 |
| Last Update Posted : | February 2, 2024 |